Generic Product Sales
The Company's generic product sales were $469 million for the quarter
ended March 31, 2008, compared to $471 million in the prior year period.
U.S. Generic Sales
Sales of U.S. generic products totaled $261 million for the first quarter
of 2008, compared to $307 million in the prior year period. The $46
million decrease in sales is primarily related to lower sales of several
of the Company's products including Ondansetron ODT, Cyclosporine Capsules
and Desmopressin. These decreases were partially offset by increases in
sales of Fentanyl Citrate and the launch of the Company's Alendronate
Sales of generic oral contraceptives, the Company's largest single
category of generic products, were lower in the quarter, as expected,
decreasing to $93 million in the first quarter of 2008 from $113 million
in the prior year period. The decrease primarily reflects lower volume on
several products due to lower market share.
Europe and Rest of the World ("ROW") Generic Sales
Sales of European and ROW generic products were $208 million in the first
quarter of 2008, compared to $164 million in the prior year period. This
$44 million increase is primarily related to the positive impact of
foreign currency exchange during the quarter and higher sales in the
Company's key markets of Germany, Russia and Poland.
Proprietary Product Sales
The Company's proprietary product sales were $96 million for the first
quarter of 2008, up from $89 million in the prior year period. The increase
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved